Research programme: Alzheimer's disease therapeutics - Mithridion
Latest Information Update: 15 Jan 2009
At a glance
- Originator University of Wisconsin System
- Developer Mithridion
- Class Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 12 Jan 2009 Preclinical development is ongoing in USA